MAP2K7 and cancer: The specific SHP2 inhibitor, SHP099, effectively suppressed the growth of receptor–tyrosine–kinase‐driven cancers in mouse xenograft models (Chen et al,2016) and prevented cancer resistance to inhibitors of MEK (Fedele et al,2018; Mainardi et al,2018; Wong et al,2018) and anaplastic lymphoma kinase (ALK) (Dardaei et al,2018).